Boston Scientific completed a share repurchase of 39,922,436 shares for US$2,000.11 million in the June quarter, equal to 2.69% of its stock, under a buyback first announced in December 2020, while quarterly results highlighted underperformance in U.S. Electrophysiology and Watchman alongside lower 2026 organic sales growth guidance. Although the CHAMPION-AF trial met all clinical endpoints, it did not act as a meaningful catalyst for the business outlook, and the contrast between bullish broker ratings and a Strong Sell Zacks Rank underscores growing concern around recent earnings estimate revisions. The lowered 2026 organic sales growth guidance and underperformance in U.S. Electrophysiology and Watchman weigh on what had been key growth engines, while the biggest current risk is that earnings estimates continue to drift lower if these franchises do not reaccelerate. The completed repurchase matters because it interacts with weaker guidance and mixed CHAMPION AF sentiment, reducing the share count and supporting per share metrics even as capital returns land in a period of rising skepticism about the outlook for growth.
